Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab

Satoru Senoo; Takashi Ninomiya; Go Makimoto; Kazuya Nishii; Hirohisa Kano; Hiromi Watanabe; Yusuke Hata; Toshio Kubo; Takehiro Tanaka; Katsuyuki Hotta; Yoshinobu Maeda; Katsuyuki Kiura

doi:10.2169/internalmedicine.0890-18

CASE REPORTS

Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab

Satoru Senoo, Takashi Ninomiya, Go Makimoto, Kazuya Nishii, Hirohisa Kano, Hiromi Watanabe, Yusuke Hata, Toshio Kubo, Takehiro Tanaka, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura

Author information

Satoru Senoo
Department of Respiratory Medicine, Okayama University Hospital, Japan
Takashi Ninomiya
Department of Respiratory Medicine, Okayama University Hospital, Japan
Go Makimoto
Department of Respiratory Medicine, Okayama University Hospital, Japan
Kazuya Nishii
Department of Respiratory Medicine, Okayama University Hospital, Japan
Hirohisa Kano
Department of Respiratory Medicine, Okayama University Hospital, Japan
Hiromi Watanabe
Department of Respiratory Medicine, Okayama University Hospital, Japan
Yusuke Hata
Department of Respiratory Medicine, Okayama University Hospital, Japan
Department of Respiratory Medicine, Kure Kyosai Hospital, Japan
Toshio Kubo
Department of Respiratory Medicine, Okayama University Hospital, Japan
Takehiro Tanaka
Division of Diagnostic Pathology, Okayama University Hospital, Japan
Katsuyuki Hotta
Center for Innovative Clinical Medicine, Okayama University Hospital, Japan
Yoshinobu Maeda
Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
Katsuyuki Kiura
Department of Respiratory Medicine, Okayama University Hospital, Japan

Keywords: pulmonary pleomorphic carcinoma, immune checkpoint inhibitor, PD-1, PD-L1, FGFR

JOURNAL OPEN ACCESS

2019 Volume 58 Issue 7 Pages 985-989

DOI https://doi.org/10.2169/internalmedicine.0890-18

Browse “Advance online publication” version

Details

Abstract

Pulmonary pleomorphic carcinoma (PPC) is a rare very aggressive subtype of non-small cell lung cancer. We herein report a case of PPC that showed a rapid response to nivolumab. The patient, whose multiple tumors had progressed very aggressively, was treated with nivolumab, an anti-programmed cell death-1 (PD-1) antibody. The tumors dramatically shrank after one cycle of nivolumab. The tumors were positive for programmed cell death ligand 1 (PD-L1). An immunohistochemical analysis revealed numerous PD-1⁺, CD68⁺ and CD206⁺ macrophages. This PD-1 antibody may be a good treatment option, especially in tumors that express PD-L1 and which show PD-1⁺ macrophage infiltration.

Corresponding author

Register with J-STAGE for free!